IBD: Crohn's Disease
Transition Pathway Brochure for IBD Patients
Helping inflammatory bowel disease (IBD) patients best understand transitioning/switching from a reference biologic to a biosimilar.
Related Articles
Patient Survey BC PharmaCare and Alberta Health coverage is changing for people who take Remicade® (infliximab) for the treatment of Crohn’s disease or ulcerative colitis. In […]
It is estimated that 104,000 Canadians had ulcerative colitis in 2012, with 4,500 new cases annually. (Crohn’s and Colitis Foundation of Canada 2012) In 2008, physician […]
